RESEARCH MONOGRAPH · KDC-MN-310

Pentoxifylline

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

76/100

Old-school methylxanthine PDE inhibitor that quietly does interesting hemorheologic work, slept-on as an anti-inflammatory research tool

Pentoxifylline is a methylxanthine relative of caffeine that Hoechst developed in the 70s as Trental, primarily for peripheral arterial disease and intermittent claudication. The mechanism is genuinely multi-target: non-selective phosphodiesterase inhibition (raising intracellular cyclic AMP across multiple cell types), and downstream effects on red blood cell deformability, platelet aggregation, and inflammatory cytokine production. The hemorheologic effects are the indication-defining piece (improved RBC flexibility, reduced blood viscosity, improved tissue perfusion in low-flow states), but the anti-inflammatory pharmacology is what makes pentoxifylline research-interesting in our context.

The TNF-alpha suppression effect is the more interesting pharmacology and it's been studied across multiple indications. Pentoxifylline reduces TNF-alpha production by macrophages in vitro and in vivo, with downstream effects on inflammatory cascades that have produced positive trial data in alcoholic hepatitis (the Cochrane review here is mixed but the early Akriviadis trial was the reference), diabetic nephropathy (multiple trials, modest but real renoprotective effect on top of ACE inhibition), and a tail of other inflammatory indications where the signal is real but heterogeneous.

What we like: well-characterized polypharmacology, decades of clinical safety data, and a useful research tool for studying combined PDE inhibition and TNF-alpha modulation. The hemorheologic mechanism is unique enough in the small-molecule world to make pentoxifylline genuinely useful for perfusion-relevant research.

What we dont love is the modest clinical effect sizes. Pentoxifylline's effects on intermittent claudication are real but small (modest improvement in pain-free walking distance in meta-analyses), and the broader inflammatory indications produce signal without home runs. The compound is reliable but doesnt produce headline-magnitude effects in most studies.

The contemporary research interest tends to be in the TNF-alpha and inflammatory pathways rather than the hemorheologic profile, which is interesting from a positioning standpoint because the FDA indication (intermittent claudication) is the application thats most clinically modest. The research literature has moved past the original indication in interesting ways.

Sourcing is excellent. Pentoxifylline is pharma-grade, USP-monographed, dirt cheap, and reliably available. HPLC purity is straightforward, the molecule is stable, and the failure modes are minimal. One of the easiest-sourced compounds in our catalog.

Evidence: 70
Mechanism: 78
Reliability: 70
Safety: 82
Sourcing: 90
Value: 85
Signal: 65
Staying power: 70

Plain-language summary Intrigue 42 / 100

Pentoxifylline (Trental) is a methylxanthine, structurally related to caffeine and theophylline, approved in 1984 for intermittent claudication (leg pain from peripheral artery disease while walking). Mechanism is weak, non-selective inhibition of phosphodiesterases (PDE3, 4, 5), but the practically meaningful effect is making red blood cells more deformable and reducing platelet aggregation, improving microcirculatory blood flow through narrowed vessels. Off-label exploration includes alcoholic hepatitis, vascular dementia, and tinnitus, with mixed results. The clinical effect in claudication is real but modest, and exercise therapy and surgical revascularization have largely overtaken it. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Methylxanthine PDE inhibitor / hemorheologic agent

A methylxanthine non-selective phosphodiesterase inhibitor that improves erythrocyte deformability and microcirculation; used for intermittent claudication.

Abstract

Pentoxifylline (1-(5-oxohexyl)-3,7-dimethylxanthine; CAS 6493-05-6; molecular formula C13H18N4O3; molecular weight 278.31) is a methylxanthine non-selective phosphodiesterase inhibitor developed at Hoechst (now Sanofi) and approved by the FDA in 1984 under the trade name Trental. Mechanism: weak non-selective PDE inhibition (PDE3, PDE4, PDE5) increases intracellular cAMP and cGMP. The principal clinically meaningful effect is improvement in erythrocyte deformability and reduced platelet aggregation, producing improved microcirculatory blood flow. Approved for intermittent claudication. Off-label use in chronic cognitive impairment from small-vessel cerebrovascular disease, peripheral neuropathy, and tinnitus. Plasma half-life is approximately 0.4 to 0.8 hours; metabolism is hepatic. Used as a reference hemorheologic agent and weak non-selective PDE inhibitor.

Mechanism of action

Weak non-selective phosphodiesterase inhibition (PDE3-5); increases erythrocyte deformability and reduces platelet aggregation.

Reported research dose ranges

Clinical 400 mg in the published literature.

References

Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995.
Salhiyyah K, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2015.
Gordon MN, et al. Pentoxifylline in dementia. Drugs Aging 1992.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-310

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pentoxifylline

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs